Synonym
ABN401; 2242563-15-9; SCHEMBL17075616; EX-A6500; MS-30262
IUPAC/Chemical Name
2-((6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)-4-(5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)pyrimidin-2-yl)morpholine
InChi Key
PQJGYYZYYMVBDF-UHFFFAOYSA-N
InChi Code
InChI=1S/C29H34N12O/c1-37-7-9-39(10-8-37)17-21-3-5-22(6-4-21)23-13-31-29(32-14-23)40-11-12-42-25(19-40)20-41-28-27(35-36-41)30-16-26(34-28)24-15-33-38(2)18-24/h3-6,13-16,18,25H,7-12,17,19-20H2,1-2H3
SMILES Code
CN1N=CC(C2=CN=C3C(N(CC4CN(C5=NC=C(C6=CC=C(CN7CCN(C)CC7)C=C6)C=N5)CCO4)N=N3)=N2)=C1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
566.67
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kim J, Park KE, Jeong YS, Kim Y, Park H, Nam JH, Jung K, Son WS, Jung HS, Lee
JH, Jeong SH, Kim NA, Ha JD, Cho SY, Choi YL, Chung SJ, Choi JY, Hong S, Shin
YK. Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor,
Based on Diagnostic Biomarker Test in MET-Addicted Cancer. Cancers
(Basel). 2020 Jun 15;12(6):1575. doi: 10.3390/cancers12061575. PMID: 32549194;
PMCID: PMC7352216.
2: Ravi M, Julu T, Kim NA, Park KE, Jeong SH. Solubility Determination of c-Met
Inhibitor in Solvent Mixtures and Mathematical Modeling to Develop
Nanosuspension Formulation. Molecules. 2021 Jan 13;26(2):390. doi:
10.3390/molecules26020390. PMID: 33450987; PMCID: PMC7828412.
3: Kim NA, Hong S, Kim KH, Choi DH, Kim JS, Park KE, Choi JY, Shin YK, Jeong SH.
New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor
Effect in c-Met-Amplified NSCLC. Pharmaceutics. 2020 Feb 3;12(2):121. doi:
10.3390/pharmaceutics12020121. PMID: 32028611; PMCID: PMC7076440.
